Eric Jansen, a physicist affiliated with the Balanced Veterans Network, urged the Food and Drug Administration to consider psychedelic drugs for severe mental health conditions. This advocacy aligns with recent directives from Health and Human Services Secretary Robert F. Kennedy Jr., who emphasized the need for faster FDA review of such treatments.

Jansen participated in a discussion with Department of Veterans Affairs officials in Orlando in August 2026 regarding the implementation of innovative therapies for veterans. The meeting included senior advisor Andrew Gradison and focused on the potential integration of psychedelics into veteran care protocols.

Kennedy’s push for expedited reviews followed an executive order issued by President Donald Trump in April 2026. The secretary has also delegated some responsibilities to Stephanie Haridopolos, whom he appointed as director of health communications.

Beyond the specific focus on psychedelics, other medical professionals addressed distinct clinical and systemic issues. Malinda Itchins, affiliated with Royal North Shore Hospital and Chris O'Brien Lifehouse in Sydney, showed trial data for a ROS1-targeting lung cancer therapy.

Renuka Iyer, affiliated with Roswell Park Comprehensive Cancer Center in Buffalo, commented on the systemic drivers behind ongoing cancer drug shortages. Her analysis provided context for supply chain challenges affecting patient access to essential oncology treatments.

Nicholas Peoples, affiliated with Massachusetts General Hospital in Boston, discussed active physician involvement in societal issues like human trafficking. Bryan Carmody, affiliated with Eastern Virginia Medical School in Norfolk, reflected on proposed updates to residency training standards.

Sophie Marie Jones, affiliated with Queen's University Belfast in Ireland, contextualized data on a possible link between air pollution and suicidality. Terry Adirim, former acting assistant secretary of defense for health affairs, discussed an emergency use pathway for a sublingual ketamine product.

Aaron Carroll, president and CEO of AcademyHealth, questioned the impact of HHS Secretary Robert F. Kennedy Jr.'s eight new picks for the U.S. Preventive Services Task Force. In a separate legislative development, Ron Wyden critiqued HHS deputy secretary nominee Chris Klomp for his answers about vaccines during a Senate confirmation hearing.

Wyden, a Democrat from Oregon, stated that the nominee had provided unclear responses. "We've had a real word salad on the vaccine issue," Wyden said during the hearing.

Why It Matters

The convergence of advocacy from groups like the Balanced Veterans Network and administrative action from the Department of Health and Human Services signals a potential shift in regulatory approaches to mental health treatments. The executive order issued in April 2026 established a framework for accelerating reviews, which directly impacts how agencies like the FDA evaluate psychedelic substances.

These developments occur alongside broader discussions in the medical community regarding physician roles, drug shortages, and training standards. The appointment of Stephanie Haridopolos as director of health communications indicates an organizational effort within HHS to manage messaging around these policy changes.

What's New

HHS Secretary Robert F. Kennedy Jr. emphasized the need for faster FDA review of psychedelic treatments for mental health conditions, following an executive order issued by President Donald Trump in April 2026. In August 2026, Eric Jansen participated in a discussion with VA officials in Orlando, including senior advisor Andrew Gradison, about the implementation of innovative therapies for veterans, including psychedelics.

Eric Jansen is a physicist. HHS Secretary Robert F. Kennedy Jr. has delegated some responsibilities to Stephanie Haridopolos and appointed her director of health communications.